Abivax (ABVX) Current Deferred Revenue (2021 - 2023)
Abivax's Current Deferred Revenue was $55,949 in Q4 2023, down 58.8% from $135,693 a year earlier.
Powered by 
Analysis
Abivax (ABVX) Current Deferred Revenue (2021 - 2023) Analysis & Trends
At the end of FY2023, Current Deferred Revenue at Abivax came in at $56,249, down 59.9% from FY2022.
- In earlier years, Current Deferred Revenue was $140,176 in FY2022 (-26.9%) and $191,710 in FY2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.54 Bn | 572.07 Bn | 17.26 Bn |
| 2 | AbbVie | 467.01 Bn | 440.17 Bn | 12.70 Bn |
| 3 | Merck | 367.16 Bn | 321.59 Bn | 12.21 Bn |
| 4 | Novartis Ag | 277.56 Bn | 233.43 Bn | 11.24 Bn |
| 5 | Astrazeneca | 258.23 Bn | 231.79 Bn | 12.86 Bn |
| 6 | Amgen | 224.14 Bn | 179.54 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 187.30 Bn | 161.42 Bn | 6.22 Bn |
| 8 | Pfizer | 163.47 Bn | 110.41 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.31 Bn | 105.31 Bn | 2.84 Bn |
| 10 | Abivax | 7.15 Bn | 7.15 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 55,948.88 |
| Dec 31, 2022 | 135,692.90 |
| Dec 31, 2021 | 185,323.29 |
API Access
Abivax Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ABVX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "ABVX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ABVX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();